Authors: Mariam Molokhia, Paul McKeigue, Vasa Curcin, Azeem Majeed
DOI: 10.1371/journal.pone.0002522
Abstract Summary
Statins significantly increase myopathy risk, with rates varying by drug type. Analysis of 93,831 patients showed fluvastatin and ciprofibrate posed highest risks. Risk persisted beyond 12 months of use, with annual incidence of 689 cases per million patients. Case-crossover methods in primary care databases offer powerful early detection of drug side effects.
Why Brain? 🧠
Study reveals statins significantly increase myopathy risk, with fluvastatin showing highest risk. Annual incidence: 689 cases per million patients. Risk persists beyond 12 months of use.
The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.
